Cara Therapeutics

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cara Therapeutics reports solid Q4 earnings amidst growth opportunities

Cara Therapeutics showcased strong revenue growth and positive feedback on KORSUVA injection sales in Q4 2022.
While facing challenges such as demand instability and regulatory uncertainties, the company remains confident in its growth prospects.
Strategic investments, milestone anticipation, and financial stability position Cara well for future value creation and market expansion.

Cara Therapeutics reports strong Q1 revenue, optimistic about pipeline growth

Cara Therapeutics delivered solid revenue in Q1 2023 driven by the successful launch of KORSUVA and Kapruvia. While facing increased operating expenses, the company remains optimistic about its pipeline's potential. Strategic focus on KORSUVA's success and ongoing R&D efforts position Cara for future growth.

Cara Therapeutics reports solid Q2 earnings amidst regulatory uncertainties

Cara Therapeutics posted strong financial performance in Q2 2023, driven by robust net sales and cash reserves, with a focus on maximizing shareholder value.
The company faces challenges related to potential CMS changes and European market dynamics but sees opportunities in international expansion and regulatory engagement.
Overall, Cara Therapeutics remains optimistic about the commercial prospects of its key products and pipeline, aiming for sustained growth and market leadership.

Cara Therapeutics extends cash runway, faces funding challenges ahead

Cara Therapeutics reports strong financials with extended cash runway. Progress in late-stage programs and successful monetization of royalties. Facing challenges with funding limitations and uncertainties around data releases.

Cara Therapeutics extends cash runway to 2026 amidst revenue challenges

Cara Therapeutics strategically focused on NP and oral DSK programs to drive growth.
Strong demand for KORSUVA injection but challenges from reimbursement changes.
Confidence in NP program and potential partnerships signal future opportunities.
Financially extended runway to 2026 but facing liquidity challenges with $1.8 million cash.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Korsuva has been approved in an indication for which, it faces little in the way of competition. A number of expansion opportunities await oral difelikefalin, with positive phase 2 data for NP opening the door to additional indications.

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients with NP Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients with NP

Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

ST. GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by

Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

Cara Therapeutics, Inc. (NASDAQ:CARA ) Q2 2021 Results Conference Call August 8, 2022 4:30 PM ET Company Participants Iris Francesconi - Head of Investor Relations Christopher Posner - President and Chief Executive Officer Richard Makara - Interim Chief Financial Officer Joana Goncalves - Chief Medical Officer Conference Call Participants Daniel Wolle - JPMorgan Christopher Howerton - Jefferies Joseph Stringer - Needham & Company David Amsellem - Piper Sandler Oren Livnat - H.C. Wainwright Jason Gerberry - Bank of America Operator Good afternoon.

Cara Therapeutics, Inc. (CARA) CEO Christopher Posner on Q2 2021 Results - Earnings Call Transcript

– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA ™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia ® (difelikefalin) –

Cara Therapeutics Reports Second Quarter 2022 Financial Results

Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Cara Therapeutics (CARA) Ahead of Earnings?

STAMFORD, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022, at 9:30 a.m. ET.

Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

STAMFORD, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report second quarter 2022 financial results and provide a corporate update.

Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) –

Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

Since I wrote my bullish call on Cara Therapeutics, the shares have absolutely collapsed. I thought I'd revisit the name again to see if I should add, hold, or sell. The company reported earnings, and the same trend persists: the company sells more, and loses more, and this trend needs to be reversed.

Calls A Much Safer Way To Buy Cara Therapeutics

Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates

Cara Therapeutics, Inc. (NASDAQ:CARA ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Iris Francesconi - Interim Head, Investor Relations Chris Posner - President & Chief Executive Officer Tom Reilly - Chief Financial Officer Joana Goncalves - Chief Medical Officer. Conference Call Participants Joseph Stringer - Needham & Company Chi Tran - Bank of America Daniel Wolle - JPMorgan David Amsellem - Piper Sandler Sumant Kulkarni - Canaccord Oren Livnat - H.C.

Cara Therapeutics, Inc. (CARA) CEO Chris Posner on Q1 2022 Results - Earnings Call Transcript

KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation

Cara Therapeutics Reports First Quarter 2022 Financial Results

STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the following investor conferences in May:

Cara Therapeutics to Present at May Investor Conferences

STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 9, 2022, at 4:30 p.m. ET to report first quarter 2022 financial results and provide a corporate update.

Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

ST. GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Commission has granted marketing authorization to Kapruvia® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adult hemodialysis patients. The marketing authorization, which approves Kapruvia® for use in all member states of the Eu

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022, at 1:30 p.m. ET.

Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Poster highlights reduction in itch intensity with difelikefalin treatment correlated with reductions in inflammatory markers in patients with chronic kidney disease-associated pruritus undergoing hemodialysis Poster highlights reduction in itch intensity with difelikefalin treatment correlated with reductions in inflammatory markers in patients with chronic kidney disease-associated pruritus undergoing hemodialysis

Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

Data presented in late-breaking session at the 2022 American Academy of Dermatology (AAD) Annual Meeting Data presented in late-breaking session at the 2022 American Academy of Dermatology (AAD) Annual Meeting

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

Cara Therapeutics, Inc. (CARA) CEO Christopher Posner on Q4 2021 Results - Earnings Call Transcript

Cara (CARA) delivered earnings and revenue surprises of -26% and 77.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics (CARA) Reports Q4 Loss, Lags Revenue Estimates

KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed

Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

ST. GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency's (EMA) CHMP has recommended approval of Kapruvia® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. The CHMP opinion is the basis for the European Commission's final decision regarding marketing a

News for Cara Therapeutics Stock (CARA)